Ocular Hypertension (OHT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Ocular Hypertension (OHT) Market Outlook

Thelansis’s “Ocular Hypertension (OHT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ocular hypertension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ocular Hypertension (OHT) Overview

Ocular hypertension (OHT) is the term used to describe a situation where a patient has an intraocular pressure (IOP) exceeding 21 mmHg. Typically asymptomatic, OHT is often incidentally discovered during routine ophthalmic examinations before it progresses into glaucomatous disorders. The underlying cause of OHT is impaired drainage of aqueous fluid from the front of the eye through the trabecular meshwork, requiring higher intraocular pressure for adequate drainage and resulting in chronically elevated IOP. It stands as a prominent modifiable risk factor for the development of glaucoma, with advancing age naturally increasing IOP and thereby raising the risk of ocular hypertension, particularly in elderly individuals. Additionally, a positive family history of glaucoma has been identified as another risk factor for OHT. In patients with OHT, the eye appears normal during the examination, featuring an open anterior chamber angle on gonioscopic evaluation. Fundus examination and imaging do not reveal signs of ocular nerve damage, and visual field findings remain normal. Uncontrolled OHT poses a significant risk of converting to glaucoma, with central corneal thickness (CCT) as a key risk factor for this transformation. Individuals with thin/low CCT measurements (less than 555 micrometers) are at a higher risk of OHT progressing to glaucoma than those with higher CCT values (greater than 488 micrometers). A more excellent cup-to-disc ratio observed during fundus examination is another statistically significant risk factor for the development of glaucoma. Additional risk factors for glaucoma conversion include:

• Age
• Race (with individuals of African ethnic background being predisposed)
• Gender (males having a higher risk)
• Pre-existing heart disease

Conversely, factors such as myopia, diabetes, and a family history of glaucoma are statistically insignificant. Management of OHT involves either treating the condition or opting for regular observation. The preferred treatment typically includes using beta-agonist or prostaglandin eyedrops administered once daily. Laser treatment and stent placement are alternative options shown to lower IOP. Treating OHT has been demonstrated to reduce the risk of glaucoma conversion from 9.5% to 4.4% over five years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: